Follow
Petar Jelinic
Petar Jelinic
Senior Research Scientist, Memorial Sloan Kettering Cancer Center, New York
Verified email at mskcc.org
Title
Cited by
Cited by
Year
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary
P Jelinic, JJ Mueller, N Olvera, F Dao, SN Scott, R Shah, JJ Gao, ...
Nature genetics 46 (5), 424-426, 2014
3372014
Loss of imprinting and cancer
P Jelinic, P Shaw
The Journal of Pathology: A Journal of the Pathological Society of Great …, 2007
2952007
The Testis-Specific Factor CTCFL Cooperates with the Protein Methyltransferase PRMT7 in H19 Imprinting Control Region Methylation
P Jelinic, JC Stehle, P Shaw
PLoS biology 4 (11), e355, 2006
2622006
Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade
P Jelinic, J Ricca, E Van Oudenhove, N Olvera, T Merghoub, DA Levine, ...
JNCI: Journal of the National Cancer Institute 110 (7), 787-790, 2018
1392018
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
Y Xue, B Meehan, E Macdonald, S Venneti, XQD Wang, L Witkowski, ...
Nature communications 10 (1), 558, 2019
1062019
Loss of SMARCA4 expression is both sensitive and specific for the diagnosis of small cell carcinoma of ovary, hypercalcemic type
N Conlon, A Silva, E Guerra, P Jelinic, BA Schlappe, N Olvera, JJ Mueller, ...
The American journal of surgical pathology 40 (3), 395-403, 2016
992016
New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair
P Jelinic, DA Levine
Molecular cancer therapeutics 13 (6), 1645-1654, 2014
952014
A novel mammalian complex containing Sin3B mitigates histone acetylation and RNA polymerase II progression within transcribed loci
P Jelinic, J Pellegrino, G David
Molecular and cellular biology 31 (1), 54-62, 2011
922011
Homologous recombination deficiency: concepts, definitions, and assays
MD Stewart, D Merino Vega, RC Arend, JF Baden, O Barbash, ...
The Oncologist 27 (3), 167-174, 2022
742022
Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type
P Jelinic, BA Schlappe, N Conlon, J Tseng, N Olvera, F Dao, JJ Mueller, ...
Modern Pathology 29 (1), 60-66, 2016
702016
Sin3B expression is required for cellular senescence and is up-regulated upon oncogenic stress
KB Grandinetti, P Jelinic, T DiMauro, J Pellegrino, ...
Cancer research 69 (16), 6430-6437, 2009
582009
Small cell cancers of the female genital tract: Molecular and clinical aspects
JR Patibandla, JE Fehniger, DA Levine, P Jelinic
Gynecologic Oncology 149 (2), 420-427, 2018
562018
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast …
EP Winer, O Lipatov, SA Im, A Goncalves, E Muņoz-Couselo, KS Lee, ...
Journal of Clinical Oncology 38 (15_suppl), 1013-1013, 2020
542020
Validated gene targets associated with curatively treated advanced serous ovarian carcinoma
JN Barlin, P Jelinic, N Olvera, F Bogomolniy, M Bisogna, F Dao, ...
Gynecologic oncology 128 (3), 512-517, 2013
512013
Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers
HU Osmanbeyoglu, F Shimizu, A Rynne-Vidal, D Alonso-Curbelo, ...
Nature communications 10 (1), 4369, 2019
272019
miR-200c-driven mesenchymal-to-epithelial transition is a therapeutic target in uterine carcinosarcomas
JH Tseng, M Bisogna, LN Hoang, N Olvera, C Rodriguez-Aguayo, ...
Scientific reports 7 (1), 3614, 2017
252017
The EMSY threonine 207 phospho-site is required for EMSY-driven suppression of DNA damage repair
P Jelinic, LA Eccles, J Tseng, P Cybulska, M Wielgos, SN Powell, ...
Oncotarget 8 (8), 13792, 2017
172017
Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 exploratory analysis
S Loi, R Salgado, P Schmid, J Cortes, DW Cescon, EP Winer, ...
JCO Precision Oncology 7, e2200317, 2023
92023
Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from …
S Loi, P Schmid, J Cortes, DW Cescon, EP Winer, DL Toppmeyer, ...
Cancer Research 81 (4_Supplement), PD14-07-PD14-07, 2021
82021
843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100
JA Ledermann, R Shapira-Frommer, AD Santin, A Lisyanskaya, S Pignata, ...
Annals of Oncology 31, S631-S632, 2020
42020
The system can't perform the operation now. Try again later.
Articles 1–20